儿童糖皮质激素性骨质疏松的防治

doi:10.11852/zgetbjzz2017-25-06-12

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (6): 582-584.DOI: 10.11852/zgetbjzz2017-25-06-12

儿童糖皮质激素性骨质疏松的防治

康小俊综述, 田执梁审校

哈尔滨医科大学附属第二医院儿科,黑龙江哈尔滨 150000

收稿日期:2016-07-04 发布日期:2017-06-10 出版日期:2017-06-10
通讯作者: 田执梁,E-mail:tianzhiliang999@aliyun.com
作者简介:康小俊(1990-),女,湖南人,土家族,在读硕士,主要研究方向为儿童哮喘。

Prevention and treatment of glucocorticoid-induced osteoporosis in children

KANG Xiao-jun, TIAN Zhi-liang

Department of Pediatrics,the 2nd Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150000,China

Received:2016-07-04 Online:2017-06-10 Published:2017-06-10
Contact: TIAN Zhi-liang,E-mail:tianzhiliang999@aliyun.com

摘要/Abstract

摘要： 糖皮质激素在儿科疾病中应用广泛,长期应用糖皮质激素可导致骨密度减低及骨折等。在成人,存在管理糖皮质激素性骨质疏松症的循证指南,儿童糖皮质激素性骨质疏松症也越来越受到儿科医师的重视,但有关儿童的信息还是非常少,本文主要对儿童糖皮质激素性骨质疏松的预防和治疗进行综述。

关键词: 骨质疏松, 糖皮质激素, 骨密度, 膦酸盐

Abstract: Glucocorticoids (GCs) is widely used in pediatric practice.Long-term systemic GC therapy is associated with many side-effects,including low bone mineral density (BMD) and fractures.In adults,evidence-based guidelines exist to base management of patients with glucocorticoid-induced osteoporosis.Children of glucocorticoid glucocorticoid-induced osteoporosis is becoming more and more brought to the attention of the pediatrician,but information about children is still very few.This article mainly summarized the prevention and treatment of glucocorticoid-induced osteoporosis in children.

Key words: osteoporosis, glucocorticoid, bone mineral density, diphosphonate

中图分类号:

R179

康小俊综述, 田执梁审校. 儿童糖皮质激素性骨质疏松的防治[J]. 中国儿童保健杂志, 2017, 25(6): 582-584.

KANG Xiao-jun, TIAN Zhi-liang. Prevention and treatment of glucocorticoid-induced osteoporosis in children[J]. journal1, 2017, 25(6): 582-584.

参考文献

[1] Bishop N,Arundel P,Clark E,et al.Fracture prediction and the definition of osteoporosis in children and adolescents:the ISCD 2013 pediatric official positions[J].Journal of Clinical Densitometry,2014,17(2):275-280.
[2] Celia R,Bianca L,Ramsay T,et al.Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation:A national observational study[J].Arthritis Care & Research,2012,64(64):122-131.
[3] Phan V,Blydt-Hansen T,Feber J,et al.Skeletal findings in the first 12?months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome[J].Osteoporosis International,2014,25(2):627-637.
[4] Alos N,Grant RM,Ramsay T,et al.High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2012,30(22):2760-2767.
[5] Leblanc CMA,Ma J,Scuccimarri R,et al.A154:Glucocorticoid therapy and the risk of incident vertebral fracture in children with rheumatic disorders[J].Arthritis & Rheumatology,2014,66(Suppl11):199-200.
[6] Faienza MF,Brunetti G,Ventura A,et al.Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome[J].Bone,2015,81:228-236.
[7] Divasta AD,Feldman HA,Giancaterino C,et al.The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa.[J].Metabolism Clinical & Experimental,2012,61(7):1010-1020.
[8] Divasta AD,Feldman HA,Beck TJ,et al.Does hormone replacement normalize bone geometry in adolescents with anorexia nervosa?[J].Journal of Bone & Mineral Research the Official Journal of the American Society for Bone & Mineral Research,2014,29(1):151-157.
[9] Hirota T,Hirota K.Bone and Nutrition.Nutritional management of osteoporosis[J].Clinical Calcium,2015,25(7):1049-1055.
[10] Ma NS,Gordon CM.Pediatric osteoporosis:where are we now?[J].Journal of Pediatrics,2012,161(6):983-990.
[11] Thomas T,Horlait S,Ringe J D,et al.Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice[J].Osteoporosis International,2013,24(1):263-269.
[12] Tee SI,Yosipovitch G,Chan YC,et al.Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate:a randomized,double-blind,placebo-controlled study[J].Archives of Dermatology,2012,148(3):307-314. [13] Hakala M,Kröger H,Valleala H,et al.Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases:a 12-month,randomized,double-blind,placebo-controlled trial[J].Scandinavian Journal of Rheumatology,2012,41(4):260-266.
[14] Cheung MS.Drugs used in paediatric bone and calcium disorders[J].Endocr Developm,2015,28:277-290.
[15] Munns CF,Ooi HL,Briody JN,et al.Six monthly intravenous zoledronic acid in childhood osteoporosis[J].International Journal of Pediatric Endocrinology,2013,2013(Suppl1):1-10.
[16] Ooi HL,Briody J,Biggin A,et al.Intravenous zoledronic acid given every 6 months in childhood osteoporosis.[J].Hormone Research in Paediatrics,2013,80(3):179-184.
[17] Bishop N,Adami S,Ahmed SF,et al.Risedronate in children with osteogenesis imperfecta:a randomised,double-blind,placebo-controlled trial[J].Lancet,2013,382(9902):1424-1432.
[18] Eghbali-Fatourechi G.Bisphosphonate therapy in pediatric patients[J].Journal of Diabetes & Metabolic Disorders,2014,13(1):1-11.
[19] Andrew B,Tina M L,Mary M Q,et al.Reduction in bisphosphonate side effect profile using short-term steroid cover[J].Bioscientifica,2013.doi:10.1530/boneeabs.2.P37
[20] Nardone V,D'Asta F,Brandi ML.Pharmacological management of osteogenesis.[J].Clinics,2014,69(6):438-446.
[21] El-Darouti MA,Mashaly HM,El-Nabarawy E,et al.Comparative study of the effect of a daily steroid regimen versus a weekly oral pulse steroid regimen on morphological changes,blood sugar,bone mineral density and suprarenal gland activity[J].Journal of Dermatological Treatment,2012,23(1):4-10.
[22] Misra M,Klibanski A.Endocrine consequences of anorexia nervosa[J].Lancet Diabetes & Endocrinology,2014,2(7):581-592.
[23] Mughal MZ.Fractures in children with cerebral palsy[J].Current Osteoporosis Reports,2014,12(3):313-318.
[24] Behringer M,Gruetzner S,Mccourt M,et al.Effects of weight-bearing activities on bone mineral content and density in children and adolescents:A meta-analysis[J].Journal of Bone & Mineral Research the Official Journal of the American Society for Bone & Mineral Research,2014,29(2):467-478.

儿童糖皮质激素性骨质疏松的防治

Prevention and treatment of glucocorticoid-induced osteoporosis in children

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	宋晓红, 刘影, 施姣, 赵豆豆, 魏君香, 张楠, 王淑慧. 补充钙及维生素D对2～3岁幼儿身长的影响[J]. 中国儿童保健杂志, 2022, 30(9): 1037-1040.
[2]	刘芳, 张梅, 班博. 特纳综合征患者骨质疏松的研究进展[J]. 中国儿童保健杂志, 2022, 30(7): 746-749.
[3]	张骞, 万乃君. 北京地区0~3月龄婴儿超重与骨密度的关系[J]. 中国儿童保健杂志, 2021, 29(2): 218-221.
[4]	沈朝霞, 潘圆圆, 黄荣, 周亚男, 李荣, 彭璐婷, 陈梦莹, 李晓南. 儿童骨密度与骨代谢相关因素的临床研究[J]. 中国儿童保健杂志, 2020, 28(2): 144-147.
[5]	张金, 张田, 孙慧慧, 商然, 师伟佳, 邓宇鲲, 何跃辉, 万乃君. 学龄期肥胖儿童骨密度水平及影响因素研究[J]. 中国儿童保健杂志, 2020, 28(11): 1271-1275.
[6]	赵艳,胡幼芳,秦振英,杨梓,秦锐. 江苏省0~5岁儿童骨密度水平现况研究[J]. 中国儿童保健杂志, 2019, 27(3): 296-300.
[7]	米杰. 儿童青少年期是重大慢性病防治的关键窗口[J]. 中国儿童保健杂志, 2019, 27(11): 1161-1162.
[8]	骆志红,肖昕. 6~12月龄婴幼儿超声骨密度与血脂水平的相关性研究[J]. 中国儿童保健杂志, 2018, 26(9): 1013-1016.
[9]	张艳,孙静,连冬梅,刘翱搏,向娜,李杨. 长期口服糖皮质激素对慢性病患儿情绪心理状态的影响[J]. 中国儿童保健杂志, 2017, 25(9): 887-886.
[10]	徐志强. 小剂量持续性吸入糖皮质激素2年对哮喘小儿身高体重影响的观察[J]. 中国儿童保健杂志, 2017, 25(6): 637-638.
[11]	张华丽,杨丽芳,何红茹,张月芳,张欢,张瑛,王伟. 西安市0~3岁婴幼儿超声骨密度7 207例分析[J]. 中国儿童保健杂志, 2017, 25(1): 81-84.
[12]	高永嘉, 钱莹莹, 胡卓杰, 周亚芳, 胡燕丽, 任盈盈, 凌春瀛. 整合性团体干预对小于胎龄儿体格发育及骨密度的影响[J]. 中国儿童保健杂志, 2016, 24(9): 967-970.
[13]	张海菊，姚宝珍，张晓，凌伟. 睡眠中癫痫性电持续状态与注意力缺陷多动行为发病关系研究[J]. 中国儿童保健杂志, 2016, 24(3): 302-304.
[14]	张莺,沈明强. 婴幼儿超声骨密度2 083例结果分析[J]. 中国儿童保健杂志, 2016, 24(1): 99-100.
[15]	赵艾，薛勇，陈云，邵祥龙，李宏亮，王培玉，张玉梅，母智深. 学龄前儿童锌摄入情况及其对生长发育的影响[J]. 中国儿童保健杂志, 2015, 23(2): 169-171.